Variant Summary
- Also known as
- RS113488022,VAL600GLU,V640E,VAL640GLU
- HGVS
- NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A
- Variant Type(s)
- missense_variant
- Evidence Items
- 95
Evidence Level Distribution
Level A: 5Level B: 61Level C: 17Level D: 12
Evidence Items
Showing CIViC evidence rows where gene = BRAF and variant = V600E.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| C | Predictive | Supports | Sensitivity/Response | Gastrointestinal Neuroendocrine Tumor | Trametinib,Vemurafenib,Dabrafenib | 3 |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Vemurafenib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Multiple Myeloma | Vemurafenib | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 3 |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Oxaliplatin | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Irinotecan | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Oxaliplatin,Bevacizumab,Capecitabine | 3 |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Childhood Pilocytic Astrocytoma | Vemurafenib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Ovarian Serous Carcinoma | Vemurafenib | 3 |
| C | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab | 3 |
| B | Prognostic | Supports | Poor Outcome | Multiple Myeloma | 3 | |
| C | Predictive | Supports | Sensitivity/Response | Cholangiocarcinoma | Dabrafenib,Trametinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Intrahepatic Cholangiocarcinoma | Trametinib,Dabrafenib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Intrahepatic Cholangiocarcinoma | Dabrafenib,Trametinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Cholangiocarcinoma | Vemurafenib,Irinotecan,Panitumumab | 3 |
| B | Predictive | Supports | Sensitivity/Response | Ovarian Cancer | Vemurafenib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Anaplastic Thyroid Carcinoma | Vemurafenib,Pertuzumab | 3 |
| C | Predictive | Supports | Sensitivity/Response | Laryngeal Squamous Cell Carcinoma | Vemurafenib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Anaplastic Thyroid Carcinoma | Vemurafenib | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Colorectal Adenocarcinoma | Panitumumab,Trametinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Cetuximab,Encorafenib,Binimetinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Biliary Tract Cancer | Trametinib,Dabrafenib | 3 |
| B | Diagnostic | Supports | Positive | Thyroid Cancer | 3 | |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Irinotecan,Cetuximab | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Erlotinib | 3 |
| D | Predictive | Does Not Support | Resistance | Melanoma | Mirdametinib,Trametinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Panitumumab,Sorafenib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | PLX4720,Pictilisib Bismesylate | 3 |
| D | Predictive | Supports | Sensitivity/Response | Melanoma | Nutlin-3,PLX4720 | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Capecitabine,Bevacizumab,Vemurafenib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Melanoma | Dactolisib,Selumetinib | 2 |
| B | Predictive | Supports | Sensitivity/Response | Hairy Cell Leukemia | Vemurafenib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Panitumumab | 2 |
| C | Predictive | Supports | Sensitivity/Response | Multiple Myeloma | Vemurafenib | 2 |
| C | Prognostic | Does Not Support | Poor Outcome | Colorectal Cancer | 2 | |
| C | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Melanoma | Pictilisib | 2 |
| B | Prognostic | Does Not Support | Poor Outcome | Melanoma | 2 | |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib | 2 |
| B | Predictive | Does Not Support | Resistance | Melanoma | MEK Inhibitor RO4987655 | 2 |
Page 2 of 2